Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)
Vikas Gupta(Indian Institute of Technology Kanpur), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Giuseppe Prosperini(Mario Negri Sud Foundation), Alessandra Di Lelio(Mario Negri Sud Foundation), Lee Potiphar(John Radcliffe Hospital), John P. Galvin(Incyte (United States)), Adam J. Mead(National Institute for Health and Care Research), Rebecca B. Klisovic(Goethe University Frankfurt), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Lorenzo Marfisi(Mario Negri Institute for Pharmacological Research), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Alicia Orellano, Rona Singer Weinberg(University of North Carolina at Chapel Hill), Abdulraheem Yacoub(The University of Kansas Cancer Center), John Mascarenhas(Tisch Hospital), Amylou C. Dueck(Mayo Clinic in Arizona), Eliseo Serone(University of L'Aquila), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Gianni Tognoni(Mario Negri Institute for Pharmacological Research)
Cited by 2
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k